By acquiring Toronto's
DecisionLine Clinical Research Corp., Cincinnati-based
Kendle Corp. gets one of the 100-fastest growing companies in Canada, a medical research firm that has seen its revenue grow 60 percent each year, on average, since 2002. It also gets DecisionLine's expertise in early-phase studies of new drugs under development, one of the fastest-growing segments of the drug research business. DecisionLine specializes in early-phase studies to measure the effects of central nervous system drugs.
Growth in phase one testing of new drugs is expected to outpace that of the other phases of drug development by 15 percent annually, says Kendle President Simon Higginbotham. "Early phase development remains an important need for our customers and an area of significant growth opportunity for Kendle," says Higginbotham. Kendle, whose headquarters is in downtown Cincinnati, already does phase-one work at a facility in Utrecht, The Netherlands, and in Morgantown, W.Va., near West Virginia University.
Writer: David Holthaus
Source: Lori Dorer, Kendle
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.